Optimizing Patient Analgesic Experience During IVF

July 14, 2022 updated by: University of Alberta

This study is for patients undergoing In Vitro Fertilization (IVF). The investigators are studying the best way to control pain during the egg retrieval process. The egg retrieval involves passing a needle under ultrasound guidance through the vagina into the ovaries to remove eggs that are to be later fertilized. Patients often report this as very uncomfortable.

Different fertility clinics across the country use different methods of pain control. All clinics will use intravenous medication to control pain, while some may or may not use local anaesthetic (freezing) in the vagina. Our goal is to find the best way to control pain. Since local anaesthetic injection involves multiple needle punctures and may be painful, the investigators are unsure if local anaesthetic is necessary in addition to the intravenous pain medication.

The investigators will conduct a randomized trial where all patients will receive intravenous pain medication, but some will receive local anaesthetic injection and some will receive placebo injection. Patients will be asked to complete a questionnaire on their pain experience after oocyte retrieval. The investigators will then analyze the data and determine whether local anaesthetic actually improves pain when patients are already receiving intravenous pain medications. Through our study, the investigators aim to improve the pain experience of all women undergoing IVF in the future.

Study Overview

Detailed Description

Background:

A UK telephone survey (Bokhari, 1999) showed that during TUGOR, 48% of UK fertility centers were using conscious sedation, 29% general anaesthesia, 12% conscious sedation with regional anaesthesia (neuraxial block or PCB), and 2% regional anaesthesia alone. A review article (Blahos 2009) details the many different types of anaesthesia used during TUGOR. These may include combinations of the following: general anaesthesia, regional anaesthesia, local anaesthesia, conscious sedation, and alternative methods of anaesthesia (electro-acupuncture, patient controlled sedation). No recent studies were found detailing the frequency of each of the various anaesthetic options in use at fertility centers across North American.

A prospective, randomized, double-blind and placebo controlled study (Ng, 1999) showed that paracervical block combined with conscious sedation was superior to conscious sedation alone. This study used a combination of drugs (mepiridine and diazepam) not used at our center. The use of fentanyl and midazolam was first described by Harrison in 1992 for conscious sedation. In 2001 Sephton et al published a cross over audit of patient preferences comparing mepiridine, diazepam and promethazine to fentanyl and midazolam, showing superiority of fentanyl and midazolam. Midazolam has sedative and amnestic properties, whereas diazepam has no amnestic properties. The amnestic properties of midazolam make it a superior medication for overall patient experience during TUGOR, as they are less likely to recall potentially painful parts of their procedure. Midazolam has also been shown to act synergistically with fentanyl, thereby decreasing not only the actual pain recalled, but the actual pain experienced by patients. Since the only randomized control trial demonstrating the benefits of paracervical block was performed using mepiridine and diazepam, we intend to repeat the study using the superior combination of fentanyl and midazolam.

Study Rationale:

The oocyte retrieval may be the most painful part of fertility treatment. Our goal is to minimize patient discomfort and improve overall patient experience during fertility treatments. We do not know if PCB improves pain scores in the era of wider use of fentanyl and midazolam for sedation. Fertility centres may be subjecting their patients to a painful PCB injection without proven benefit. This study aims to assess whether a PCB in addition to conscious sedation can be abandoned without impacting the patient's overall pain experience.

Study Objective:

The objective is to compare whether conscious sedation alone is as effective as paracervical block plus conscious sedation in controlling pain during oocyte retrieval

Study Question:

Is conscious sedation alone as effective as paracervical block plus conscious sedation in controlling pain during oocyte retrieval?

Overview of the Trial Design This study is designed to be a placebo-controlled, randomised, double blind trial to compare whether conscious sedation with a normal saline paracervical block (placebo) is as effective as conscious sedation with a lidocaine paracervical block in controlling pain during oocyte retrieval. A total of 300 women will randomly be assigned in a 1:1 ratio, after consenting to study participation. Short-Form McGill Pain scores will be assessed in study subjects.

Study Population:

Women presenting for oocyte retrieval after a cycle of IVF stimulation at the University of Alberta Regional Fertility Centre

Study Design:

Women consenting to participate in the study will be randomly allocated to one of two groups. The control group will receive conscious sedation with a placebo (normal saline) paracervical block (PCB). The study group will receive conscious sedation with a local anaesthetic (lidocaine 1%) PCB. Computer generated randomisation will be used to determine group allocation. Group allocation will be concealed using opaque envelopes to ensure blinding. An OR nurse will prepare the PCB syringe with either lidocaine or normal saline depending on the patient's allocation. The contents of the PCB will remain blinded from the physician performing the TUGOR and the patient.

The fertility centre's routine for TUGOR is as follows: Initially conscious sedation is administered by OR nursing staff according to the patient's weight (midazolam 1 - 2 mg and fentanyl 50 - 75 ug IV). This is followed by the PCB 5 minutes later. Additional fentanyl is administered throughout the procedure as required to ensure patient comfort. The oocyte retrieval proceeds once the PCB is completed. Following the oocyte retrieval and when the conscious sedation has worn off; the patient will be assessed before discharge. Once the discharge criteria have been met, the validated and standardized Short-Form McGill Pain Questionnaire will be used to objectively measure the pain experienced during the TUGOR. All study participants will be required to rate the pain experience during the procedure. The attending nurse is required to record all adverse events from the procedure as part of her clinical duties. Embryology information, i.e. fertilization, embryo grading, development and frozen rates will be recorded to assess whether PCB affects this aspect of ART. Additional information will be obtained by reviewing participants' clinic charts nine months post-procedure to determine secondary outcomes, i.e. live birth rates. Animal mouse models in the past have shown local anaesthetic to adversely affect fertilization and embryo development (Schnell, 1992). No adverse effects on human embryos from lidocaine have ever been demonstrated (Wikland 1990), however assessing embryo quality and birth outcomes has been the standard when conducting studies assessing the use of PCB

Setting:

Academic referral fertility centre

Study Type

Interventional

Enrollment (Actual)

308

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alberta
      • Edmonton, Alberta, Canada, T5H 3V9
        • Fertility and Womens Endocrine Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 41 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women undergoing oocyte retrieval who have consented to participation
  • Only the first ART cycle will be included

Exclusion Criteria:

  • History of drug sensitivity to local anaesthetic agents
  • Women with any chronic pain syndrome

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Normal Saline
Conscious sedation and sterile normal saline (placebo) paracervical block
Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
Other Names:
  • Sterile Normal Saline
Active Comparator: Lidocaine
Conscious sedation and Lidocaine hydrochloride 1% solution paracervical block
Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
Other Names:
  • Xylocaine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain scores rated on SF-MPQ
Time Frame: Data collection is scheduled to proceed until 308 participants have been recruited which is anticipated to take up to 2 years.
Score rating will be done before the patient is discharged following oocyte retrieval.
Data collection is scheduled to proceed until 308 participants have been recruited which is anticipated to take up to 2 years.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Embryology data
Time Frame: Assessed within 7 days of oocyte retrieval
Recorded as number of embryos obtained. Number of embryos transferred. The decision to transfer Day 3 embryos or Day 5 blastocysts. Number of embryos or blastocysts frozen. Embryological grading of all embryos or blastocysts either transferred or frozen.
Assessed within 7 days of oocyte retrieval

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Live Birth Rates
Time Frame: Within 12 months of oocyte retrieval
Recorded as the number of infants born alive to the patient that resulted from embryos transferred during this study.
Within 12 months of oocyte retrieval

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tarek Motan, MB ChB, University of Alberta

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2013

Primary Completion (Actual)

November 7, 2015

Study Completion (Actual)

November 7, 2015

Study Registration Dates

First Submitted

March 8, 2013

First Submitted That Met QC Criteria

March 17, 2013

First Posted (Estimate)

March 20, 2013

Study Record Updates

Last Update Posted (Actual)

July 18, 2022

Last Update Submitted That Met QC Criteria

July 14, 2022

Last Verified

December 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infertility

Clinical Trials on Sterile Normal Saline%

3
Subscribe